Is there a role for mitomycin C in metastatic colorectal cancer?

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;19:225-49
   Web of Science ®Google Scholar
• Tanabe M, Ito Y, Tokudome N, Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer 2009;16(4):301-6
   PubMed Web of Science ®Google Scholar
• Berghmans T, Gourcerol D, Lafitte JJ, Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study. Lung Cancer 2008;61:378-84
   PubMed Web of Science ®Google Scholar
• Horvath A, Mostafid H. Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. BJU Int 2009;103:726-9
   PubMed Web of Science ®Google Scholar
• Yer VN, Szybalski W. Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA. Science 1964;145:55-8
   PubMed Web of Science ®Google Scholar
• Iyer VN, Szybalski W. A molecular mechanism of mitomycin action: linking of complementary DNA strands. Proc Natl Acad Sci USA 1963;50:355-62
   PubMed Web of Science ®Google Scholar
• Moore HW. Bioactivation as a model for drug design bioreductive alkylation. Science 1977;97:527-32
   Web of Science ®Google Scholar
• Schwartz HS, Sodergren JE, Philips FS. Mitomycin C: chemical and biological studies on alkylation. Science 1963;142:1181-83
   PubMed Web of Science ®Google Scholar
• Tomasz M, Chawla AK, Lipman R. Mechanism of monofunctional and bifunctional alkylation of DNA by mitomycin C. Biochemistry 1988;27(9):3182-7
   PubMed Web of Science ®Google Scholar
• Gobert C, Bracco L, Rossi F, Modulation of DNA topoisomerase I activity by p53. Biochemistry 1996;35(18):5778-86
   PubMed Web of Science ®Google Scholar
• Matsumura T, Takigawa N, Kiura K, Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity. In Vivo 2005;19(4):717-21
   PubMed Web of Science ®Google Scholar
• Boyer J, McLean EG, Aroori S, Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004;10(6):2158-67
   PubMed Web of Science ®Google Scholar
• Lansiaux A, Bras-Goncalves RA, Rosty C, Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11. Anticancer Res 2001;21(1A):471-6
   PubMed Web of Science ®Google Scholar
• Kano Y, Suzuki K, Akutsu M, Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50(4):604-10
   PubMed Web of Science ®Google Scholar
• Sawada N, Ishikawa T, Fukase Y, Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4(4):1013-9
   PubMed Web of Science ®Google Scholar
• Miwa M, Ura M, Nishida M, Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34(8):1274-81
   PubMed Web of Science ®Google Scholar
• Eda H, Fujimoto K, Watanabe S, Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993;32(5):333-8
   PubMed Web of Science ®Google Scholar
• Franchi F, Barone C, Seminara P, 5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures. Med Oncol Tumor Pharmacother 1991;8:75-8
   Google Scholar
• Comella P, Biglietto M, Casaretti R, Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group. Oncology 2001;60:127-33
   PubMed Web of Science ®Google Scholar
• Philip J Gold, Gail Carter, Gary Goodman, Phase II trial of irinotecan (CPT-11) and mitomycin C (MMC) in the treatment of metastatic colorectal cancer [abstract 680]. ASCO Annual Meeting; 18 – 21 May 2002; Orlando, USA
   Google Scholar
• Bamias A, Papamichael D, Syrigos K, Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. J Chemother 2003;15:275-81
   PubMed Web of Science ®Google Scholar
• Hejna M, Köstler WJ, Raderer M, Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. Anticancer Drugs 2000;11:629-34
   PubMed Web of Science ®Google Scholar
• Yamada Y, Shirao K, Hyodo I, Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. Cancer Chemother Pharmacol 2003;52:125-30
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Kornek GV, Brugger S, Randomized phase II study of irinotecan plus mitomycin C vs oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Cancer Invest 2002;20:60-8
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Hartmann JT, Willer A, Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial. Br J Cancer 2004;91:834-8
   PubMed Web of Science ®Google Scholar
• Rao S, Cunningham D, Price T, Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 2004;91:839-43
   PubMed Web of Science ®Google Scholar
• Watkins D, Rao S, Cunningham D, Abstract No: 1109. ASCO Annual Meeting; 31 May – 3 June 2003; Chicago, USA
   Google Scholar
• Tebbutt NC, Gebski V, Wilson K, International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. Abstract No: 4023. ASCO Annual Meeting; 29 May – 2 June 2009; Orlando, USA
   Google Scholar
• Lim DH, Park YS, Park BB, Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2005;56:10-4
   PubMed Web of Science ®Google Scholar
• Chong G, Dickson JL, Cunningham D, Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005;93:510-4
   PubMed Web of Science ®Google Scholar
• Harba A, Jordan K, Kegel T, Capecitabine/mitomycin C as salvage therapy in oxaliplatin and CPT11 refractory advanced colorectal carcinoma (ACRC). Abstract No: 1335. ASCO Annual Meeting; 31 May – 3 June 2003; Chicago, USA
   Google Scholar
• Gyldenkerne N, Glimelius B, Frödin JE, A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. Acta Oncol 2004;43:276-9
   PubMed Web of Science ®Google Scholar
• Gennatas CG, Michalaki V, Gennatas S. Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer [abstract 486]. Gastrointestinal Cancers Symposium; 15 – 17 January 2009; San Fransisco, USA
   Google Scholar
• Hartmann JT, Oechsle K, Quietzsch D, Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer 2003;89:2051-6
   PubMed Web of Science ®Google Scholar
• Chester JD, Dent JT, Wilson G, Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Ann Oncol 2000;11:235-7
   PubMed Web of Science ®Google Scholar
• Seitz JF, Perrier H, Giovannini M, 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma. J Chemother 1998;10:258-65
   PubMed Web of Science ®Google Scholar
• Tassinari D, Arcangeli V, Panzini I, Can mitomycin C represent a valid partner for 5-fluorouracil in second-line chemotherapy of colorectal cancer? Ann Oncol 2000;11:1071
   PubMed Web of Science ®Google Scholar
• Sobrero A, Guglielmi A, Cirillo M, 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. Br J Cancer 2001;84:1023-8
   PubMed Web of Science ®Google Scholar
• Conti JA, Kemeny NE, Saltz LB, Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. Cancer 1995;75:769-74
   PubMed Web of Science ®Google Scholar
• Ross P, Norman A, Cunningham D, A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995-1001
   PubMed Web of Science ®Google Scholar
• Price TJ, Ross PJ, Hickish T, Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer 2004;3:235-42
   PubMedGoogle Scholar
• Maisano R, Caristi N, Mare M, Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study. Anticancer Res 2007;27:2871-5
   PubMed Web of Science ®Google Scholar
• Massacesi C, La Cesa A, Marcucci F, Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology 2006;70(4):294-300
   PubMed Web of Science ®Google Scholar
• Flam M, John M, Pajak TF, Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-39
   PubMed Web of Science ®Google Scholar
• Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 1985;3:723-34
   PubMed Web of Science ®Google Scholar
• Acheson DW, Donohue-Rolfe A. Cancer-associated hemolytic uremic syndrome: a possible role of mitomycin in relation to Shiga-like toxins. J Clin Oncol 1989;7:1943
   PubMed Web of Science ®Google Scholar
• Herrmann R. 5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion. Ann Oncol 1998;9(3):342
   PubMed Web of Science ®Google Scholar